CDK4 and neoplasm: Evidence that CDK4/6 inhibitors reduce angiogenesis is model-dependent, but suppression of E2F-dependent pro-angiogenic programs, including VEGF, has been reported in some studies and may contribute to decreased tumor vascularization (55, 61).